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     INTRODUCTION 
  Clinical trials stand to bring the most benefit to regions of 
the world most affected by disease, however these communi-
ties are underrepresented in trials and these regions have lim-
ited capacities for research. In Europe and the United States 
the pharmaceutical industry’s drug and vaccine development 
programs have benefited greatly from using adaptive design 
in clinical trials as fewer patients are needed and develop-
ment times can be drastically lowered. As yet these methods 
are sparsely in academic studies and rarely, if at all, in the field 
of Global Health. Some of the highest causes of death in the 
world’s poorest regions could be improved by making changes 
in the way the disease is managed or simply by changing the 
way existing treatments are used, but these changes require evi-
dence gathered through clinical research. These disease man-
agement studies could be particularly well suited to adaptive 
design because one of the main features is that this approach 
moves away from the standard phase I, II, and III model of 
separate protocols to a single study that adapts flexibly in real 
time as knowledge is gained. Disease management trials could 
logically and safely progress from the learning phase to con-
firmatory within a single protocol. This would save time and 
money and bring about evidence for improvement compared 
with conventional methods that are now being used through 
traditional clinical trial design approaches (  Figure 1  ). 
   What is adaptive trial design?   Adaptive design is a relatively 
new approach to clinical studies that is being increasingly 
used within the pharmaceutical industry.  1   It is recognized 
that conventional randomization can be ethically infeasible 
as it gathers information and ignores current knowledge.  2  
This design approach has an in-built capacity to change the 
study; in fact, the very point is to change the study while it 
is in process without compromising the integrity of the trial. 
Adaptive design moves away from the traditional phase I–III 
categories and allows within a single protocol the ability to 
move between what would be the normal divides between the 
phases in clinical trials. In drug and vaccine development the 
use of adaptive design shortens product development time 
and therefore is very cost-effective for industry.  3–  5   However, 
adaptive design is still not mainstream, which many find 
surprising.  2  
  Adaptive clinical trial design is defined as a design that 
allows modifications to the trial and/or statistical procedures 
of the trial after its initiation without undermining its valid-
ity and integrity. The role of adaptive design is to make clini-
cal trials more flexible, efficient, and fast. Because of the level 
of flexibility involved, these trial designs are also termed as 
flexible designs. In essence a clinical trial that uses adaptive 
design allows, and indeed plans for, substantial change as the 
trial progresses without the need for a separate new study or a 
protocol amendment. 
  In the setting of clinical trials in Global Health adaptive 
design could be very exciting, not only for product devel-
opment time but for disease management trials where the 
approach could be used effectively. In disease management 
trials the typical phase I, II, and III approaches are applied but 
this is cumbersome and often illogical as these phases were 
developed to facilitate new drug and vaccine registration tri-
als. In disease management trials a more pragmatic and ratio-
nale approach is needed and adaptive design could work well. 
Although the use of adaptive design is being widely cham-
pioned, the opportunities that this approach could bring to 
research in developing countries has not been considered.  6  
  For example, let us use the theoretical example of giving an 
intramuscular antibiotic preventative treatment before deliv-
ery to assess whether the incidence of maternal and neonatal 
sepsis can be reduced. This is a possible disease management 
question that a developing country research group might wish 
to explore. If the normal clinical development trial approach 
is used then there would be at least two trials, a phase II and 
then a phase III. The phase II trial would look closely at a 
small group of mothers in a tightly controlled setting, such as 
a maternity ward in a research facility, to establish safety and 
dose and get an indication of efficacy in the small numbers 
used. Once this study was completed, reported, and published 
the phase III trial could then be planned and further funding 
obtained. The phase III trial would then be the real test of effi-
cacy, confirmation of safety, and give a better idea of effective-
ness as a larger and more “real-life” situation would be used; 
therefore, in this case it could be community health centers 
rather than a hospital. 
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  If an adaptive design approach had been used then all this 
could have been achieved within a single protocol. There is 
the obvious advantage of time and costs in only taking one 
protocol through the review and approval process and all the 
setup activities. This would be highly advantageous in the field 
of Global Health as these potentially life-saving new disease 
management approaches could be tested so much faster with-
out the delay of waiting for each phase to be approved and 
receive funding. However, there is much more to adaptive 
design than just reducing the regulatory and approval steps. 
Adaptive design involves ongoing and detailed review of the 
data. This is fundamental to the approach and is the aspect that 
allows treatment arms to be added or dropped, new patient 
groups to be included and/or the dosage changed. This can 
also make trials more ethical as fewer patients are needed and 
the design should be such that it limits the exposure of par-
ticipants to less effective treatment arms and to unexpected 
side effects. 
  There are some useful definitions and guidelines on adap-
tive design, which although written for drug and vaccine reg-
istration trials (as this is largely where the approach has been 
used), the concepts are helpful and adaptable to other trial set-
tings. For example, the Food and Drug Administration (FDA) 
recently produced some guidelines for industry  7   that include 
an explanation of how adaptive designs must be prospective: 
“The term prospective here means that the adaptation was 
planned (and details specified) before data were examined in 
an unblinded manner by any personnel involved in planning 
the revision.”   The Drug Information Journal  8   published an 
early work on this when the concept was just become recog-
nized. The definition given here of “a clinical study design that 
uses accumulating data to decide on how to modify aspects of 
the study as it continues, without undermining the   validity   and 
  integrity   of the trial,” is often quoted as definitive. 
      When could it be useful?       Table 1   describes three possible 
adaptive trial designs. These examples are not finite, any 
number of approaches could be used in adaptive design 
because the aim is to be flexible and adapt the design as the 
data is gathered and knowledge is gained. 
              How do I conduct a trial using adaptive design?    To  bring 
adaptive design to clinical trials in the field of Global Health 
there are two considerations that are likely to be the most 
pertinent. First the use of technology and second having 
strong statistical support as both of these are often lacking 
in resource-limited settings because of finances and capacity. 
However, neither should deter researchers and solutions can 
be sought that are pragmatic and appropriate. Here then we 
consider the processes in operating adaptive designs and the 
statistical input that is needed to design and implement the 
trial. 
 Figure  1.     Summary  box.    
 Table 1 
    Types of adaptive trials   
Types of adaptive design Description Objective of design
Dose finding Data is reported and extracted in interim reports in as short a 
time as possible, if technology allows this can be done in close 
to real time. The data is reviewed as it accumulates and then 
decisions can be taken and implemented on lowering or raising 
doses as determined in protocol. It is adaptive as there will not 
have been a set point where the dose is changed; the design is 
purposefully flexible and adaptive.
To avoid giving therapeutic doses, or to 
overdose.
Response adapting Safety and efficacy data are captured as near to live as possible 
and further participants are randomized according to 
outcome of earlier participants. Some have called this a 
“play-the-winner” approach as subsequent participants 
are assigned to the treatment arm that has the best efficacy 
or fewer side effects.
To reduce exposure to an ineffective arm or 
to side effects.
Amending sample size Sample sizes are based on assumptions and often there is too 
little information available that allow for accurate assumptions 
to be made.  7   Therefore, many protocols set a sample size that 
may be too high or too small. The former results in a trial that 
exposes participants needless once the question has been 
answered and the latter results in the trial being unable to 
answer the question. In an adaptive design the limitation on the 
power calculations are acknowledged and as the trial begins to 
inform that assumption so the power calculation can be amended.
Allow the trial to run until the question has 
been answered and to avoid exposing 
participants to an experimental therapy 
unnecessarily.969 ADAPTIVE DESIGN IN GLOBAL HEALTH TRIALS
  Time is important in the operation of an adaptive design 
trial. The ability to collect the data, enter it into whatever soft-
ware is being used, extract this information, have it reviewed, 
and then implement the recommendation in close to real time 
is the key to success. In pharmaceutical trials there is increas-
ing use of high technology to maximize efficiency and limit the 
time taken for this process. 
  In resource-limited settings, where trials addressing key 
questions in global health are mostly conducted, the use of 
new and expensive technology is limited. In industry, new 
technology has allowed this approach to become popular and 
enables real-time analysis of the data. However, systems can 
be designed that are not prohibitively expensive and the shar-
ing of resources and methods between research groups could 
facilitate more groups using these methods. 
  The two most common technologies used are interac-
tive voice response and electronic data capture. Let us first 
  consider electronic data capture. This is becoming increasingly 
common in developing countries and many more groups are 
using open source products such as OpenClinica for their data 
management and these systems facilitate electronic data cap-
ture.  9   Other groups are increasingly using the rapidly advanc-
ing use of handheld internet devices to capture clinical trial 
data in developing countries.  10–  12   This encouraging use of new 
technology by researchers makes the ability of using real-time 
data entry and extraction a realistic option for many develop-
ing country-based researchers. 
  Interactive voice recognition is a newer technology and 
more expensive. This is used by clinical trial groups in activi-
ties such as centralized randomization or dynamic treatment 
allocations through the use of a central data base. This is still 
relatively new and it does have its limitations  13  ; in develop-
ing countries where computer and telephone access cannot 
always be relied upon, this may not always be feasible and 
the setup and operational costs could be limited. It should be 
considered, however, as it might be possible to devise a local 
scheme that offers the same feature and advantages. One pos-
sible solution would be to have an independent group respon-
sible for allocation tasks that would operate a practical system 
within tight measures put in place to protect the blinding and 
general integrity of the trial. 
  A key operational step in the running of an adaptive trial 
will be establishing and managing the data monitoring com-
mittee and the surrounding steps and processes in reviewing 
the interim data sets, passing a decision, and implementing 
the recommendation. In developing countries, capacity for 
data monitoring committees is still largely limited  14   and where 
there is experience it is unlikely to extend to the concepts and 
practices involved in adaptive trial designs. Therefore, the first 
groups running these trials will need to lead the way for others 
and establish systems and tools appropriate for this setting. It 
would be broadly beneficial if any such resources or guidance 
documents could then be shared with other groups. 
  Planning for an interim analysis is important,  15   within this 
should be consideration of the key variables that should be 
cleaned before the dataset is released to a data monitor-
ing committee.  16   Although time is important, the validity 
and integrity of the trial must be a more important priority. 
Therefore, a balance should be struck to ensure the reliability 
of the endpoints being assessed in all interim reviews and the 
need for rapid data transfer. In practice, this is likely to require 
an intelligent monitoring approach where only the key vari-
ables are checked before the data is extracted. Later, and as an 
ongoing process of the trial, more extensive quality manage-
ment can be applied and the data fully cleaned before the final 
data base is closed. 
 A more significant challenge for researchers wanting to con-
duct an adaptive trial design might be with the actual design 
rather than the implementation. Adaptive trial design is likely 
to need quite complex statistical considerations  17   and for 
many clinical trial sites in resource-limited settings statistical 
support is a limitation.  18,  19   Here, a collaborative solution could 
be found if research sites that do have good statistical support 
offered support and advice to others through an open collab-
oration. This could be facilitated through the Global Health 
Clinical Trials Program.  18  
      What do the regulations say about adaptive design and 
what will my institutional review board and ethics committee 
think of this approach?     Adaptive design is a common practice 
now in the United States and Europe and both regulatory 
authorities have a position and plenty of experience on this 
approach in trial methods  20,  21  ; where countries and institutions 
have not had the experience of this approach, difficulties 
may arise. In this situation a degree of prior education and 
sensitization of the committee might be advised. There are 
plenty of references and resources to draw upon, many of 
which have been cited here. Again, sharing experiences and 
strategies between research groups would be beneficial to the 
wider global health research community. 
    CONCLUSION 
  Clinical trials are needed to bring about improvements in 
public health as they test new drugs and vaccines and evaluate 
better ways to manage illnesses. Because developing countries 
have the largest burden of disease, they could benefit the most 
from clinical trials, but populations in these regions are under-
represented in trials compared with populations in wealthier 
regions. This is because there are too few trials and there are not 
enough people with the right skills to run trials.  22–  25   Adaptive 
trial design could make trials more cost-effective and mini-
mize patient exposure to research interventions. All the advan-
tages that adaptive design has brought to pharmaceutical trial 
stand to be at least as beneficial in resource-limited settings 
and therefore the approach is recommended to researchers in 
these settings. Disease management studies could be particu-
larly well suited to adaptive design as they could logically and 
safely progress from the learning phase to confirmatory within 
a single protocol. In no sense should adaptive design be seen 
as a shortcut or less rigorous approach, rather as an optimal 
strategy that allows for a balance between learning about an 
unknown effect to benefit future patients and the ethical obli-
gation to provide the best treatment of the patient on the trial. 
Indeed, it is unlikely that industry would have succeeded in 
widespread use of a design approach that risked suggestion of 
seeking shortcuts and weaker trial data. 
  Adaptive design clinical trials by definition allow for change 
during the trial without loss of validity. Although this stands 
to bring many advantages to enhancing research in resource-
limited setting, there are limitations and potential pitfalls. 
Less familiar design methods incorporating these method-
ological features might be off-putting for sponsors, investiga-
tors, and reviewers. However, experience is growing and more 
reports using these methods are becoming available. The FDA 970 LANG
  guidance document provides detailed notes on how risks to 
study validity and interpretation can be avoided  7   and these 
could reassure and help guide investigators and statisticians. 
  However, designing and operating adaptive clinical trials 
requires expert support, tools, resources, and training. Sharing 
of experience and best practice could facilitate more research-
ers using this approach and the Global Health Clinical Trials 
Program could provide the platform for this (  www.global
healthtrials.org ). 
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